MindMed Collaborators Dose First Patient in Phase 1 Investig

/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing...

Related Keywords

Canada , Canadian , Matthias Liechti , Miri Halperin Wernli , Exchange Commission , Company Annual Report On Form , Prnewswire Mind Medicine Mindmed Inc , Company Or Mindmed , Matthias Liechti At University Hospital Basel , Leichti Lab , Nasdaq , University Hospital Basel , Executive President , Visual Analog Scales , Annual Report , Quarterly Reports , Note Regarding Forward Looking Statements , Financial Condition , Mind Medicine Mindmed Inc ,